Using a modified "two-site" immunoradiometnc assay, termed an "interference assay," we have demonstrated the occurrence of non-analyte antibody-binding substances in approximately 40% of serum samples. These substances multivalently bind antibodies from any of several species at a site other than the antigen-binding site. Using a two-site immunoradiometnc assay for human choriogonadotropin, we have investigated their effect on analyte quantification. In this system these antibody-binding substances mimic the presence of analyte; when analyte is actually present, they can also cause over-or underestimates. Addition of excess nonspecific immunoglobulin from an appropriate species eliminates this interference. However, the amount of nonspecific immunoglobulin added to an assay system may not always be enough to block interference in all samples.
creased greatly over the past few years owing to the availability of monoclonal antibodies. This system offers the advantages of ease of application, speed, and sensitivity. Specificity is also enhanced, owing to analyte recognition by two or more antibodies. One of these, termed a "capture" antibody, is immobilized on a solid phase for easy separation of the complex, and the other, a "signal" antibody, is labeled for quantification. Careful selection of these antibodies obviates potential cross reaction by structurally related molecules. However, because the response signal of the assay depends on the amount of labeled antibody linked to the solid phase via the analyte, the presence in the sample of other substances that can multivalently bind antibodies will also produce a positive assay response. Several groups of workers have attributed falsely increased analyte values in two-site immunoassays to the presence of such non-analyte antibody-binding substances (1) (2) (3) (4) (5) (6) (7) . Because these substances constitute a considerable problem for two-site immunoassays, we undertook a detailed investigation of their prevalence, using a modified "two-site" immunoradiometric assay (IRMA),' which we have termed an "interference assay," and determined their effect on analyte quantification in a two-site IRMA for human choriogonadotropin (hCG). 
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MaterIals and Methods
Reagents
Polystyrene beads (5- Phosphate-buffered isotonic saline (PBS), pH 7.6, contained, per liter, 10 mmol of phosphate (KH2PO4/Na2HPO4), 150 mmol of NaC1, 10 mmol of EDTA (disodiurn salt), and 1 g of NaN3.
Two IgG1 murine monoclonal antibodies directed towards hCG were used.Antibody 89/9 is specific for intact hCG (8); antibody 20/4 binds hCG through the beta subunit, and thus recognizes both intact hCG and the free beta subunit.
Antibodies from tissue-culture fluid or capiylic-acid-treated ascites fluid (9) were purified by affinity chromatography on Protein A (from Staphylococcus aureus, Sigma). Antibodies 89/9 and 20/4 were radiolabeled with I by the Chloramine T method (10) and purified by gel filtration on Sephadex (350, with a 1 g/L solution of HSA in PBS as the elution buffer. Unlabeled antibody 20/4 was immobilized by adsorption onto polystyrene beads (11).
Serum Samples
Serum was specifically collected for these studies from 35 laboratory personnel, ages 19 to 45 years, and from 153 otherwiseunselected blood donors to the Red Cross Blood Bank, Sydney, Australia. All 188 subjects had no known diseases and were classed as "normal" subjects. Also included were an additional 261 samples, previously assayed for hCG and found to be negative,and 219 samples that had been assayed for thyroid hormones. Six serum samples containing rheumatoid factor and 95 containing hCG were studied separately. Serum samples were stored at -20 #{176}C until used in this investigation.
Procedures
IiUerference assay. We have developed a system that we call the interference assay for the detection of multivalent antibody-binding substances in serum. We use the same antibody as both the capture and signal antibody, on the 
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principle that only substances that can bind two or more molecules of the one antibody will produce an assay response. Any analyte that has only one antibody-binding site cannot simultaneously bind the capture and signal antibody and so cannot produce an assay response.
The procedure is as follows. Incubate 100 L of serum with 250 000 counts/mm of 'WI-labeled 20/4 antibody in 50 L of PBS and a 20/4-coated bead for 2.5 h at room temperature. Wash the bead with de-ionized water, measure its radioactivity in a gamma counter, and calculate the percentage of the 'I-labeled 20/4 that is bound to the bead (%BIT).
For some studies we substituted for 25 or 50 .cL of the PBS either serum from various animal species, dilutions of mouse or horse serum, or bovine gamma-globulin. Where required, serum samples were dilutedin hCG-free serum, which was also free of substances that bound the antibody.
The interassay CV ranged from 30% at 0.08% BIT to 10% at 0.5% B/T. Because hCG has only one 20/4-binding site per molecule, it cannot produce a response in this assay unless it polymerizes. We tested hCG up to a concentration of 2000 we coupled antibody 89/9 to Sepharose 4B and used this to produce serum free of binding substances and to purify the antibody-binding substances. The procedure is as follows. Pass 1.5 mL of test serum through a 0.5-mL affinity column. Wash the column with 3 mL ofPBS and then, to elutethe antibody-binding substances, pass 2 znL of buffer(pH 2.6, 100 mmol of glycine and 500 mmol of NaCl per liter) through the column. Assay all fractions in the interference assay to monitor the purification. This procedure removes 80 to 100% of the binding substances from serum and purifies the binding substances by 200-to 500-fold.
Results
Demonstration of Antibody-Binding Substances
Interference assay. The interference assay was developed to investigate the presence of multivalent substances binding antibody in serum. We assayed 668 serum samples, finding that bindingranged from 0.05 to >40%, indicating that a substantial number of samples contain multivalent antibody-binding substances (Figure 1 To determine the proportion of serum samples that contain significant concentrations of antibody binding substances, one must estimate the distribution of the nonspecif. Even samples having binding less than this positive cutoff value of 0.25% contain binding substances whose effects can be decreased by adding normal mouse serum (Figure 2 ). This was verified by assay of 17 serum samples from which the binding substances had been removed by immunoaffinity chromatography. For these, the %BIT value was equal to or less than that obtained when mouse serum was present, indicating that the reduction in binding effected by mouse serum is not a matrix effect.
Two-site IRMA for hCG. We investigated the degree of interferenceby multivalent antibody-binding substances in a two-site iminunoassay for analyte as exemplifiedby a twosite IRMA for hCG. We studied 190 serum samples that had been determined to be free of hCG by radioimmunoassay for hCG. While no sample negative by interference assay appeared to contain hCG, an increasing proportion of samples falsely positive for hCG was associated with an increase in the interference assay value (Figure 3) . Overall, half of the samples that were interference-assay-positive appeared to contain hCG. From these data we calculated that 15% of samples from a normal population would falsely appear to contain hCG.
We added various quantities of hCG to a sample that was interference-assay-positive, to investigate the effects of the 
Elimination of Interference
The addition of 25 pL of normal mouse serum per 100 iiL 
DiscussIon
For the same reason that the two-site immunoassay is more specific than RIA, it is also susceptible to interference by multivalent antibody-binding substances present in serum. By linking the capture and signal antibody, these substances generate an assay response signal (Figure 7) . In contrast to the analyte, they bind to a site other than the analyte-binding site of the antibody. We have investigated the occurrence of such substances in human serum by using the interference assay, a murine monoclonal "two-site" IRMA modified to minimize analyte assay response and enhance binding of the interfering substance. In this system the same anti-hCG antibody is used as the capture and signal antibody(Figure8).Only the antibody-binding substance will produce an assay response, because monomer hCG has only one binding site for the antibody, soit cannot link both the capture and signal antibody. We found that about 40% of serum samples contain significant concentrations of these multivalent antibody-binding substances, and an even greater proportion containtraceamounts. Thus the potential for clinically significant interference in two-site immunoassays is quite high.
Antbody
FIg. 7. Diagrammatic representation of anaJ,4eand intetlenng substance(I) binding in a conventional two-site immunoassay Fig. 8 . Diagrammaticrepresentation of analyte and interfering substance binding in the interference assay where the same antibody is used Symbols as in Fig. 7. The effect of the antibody-binding substances on analyte quantification was marked: 50% of the samples that were positive in the interference assay appear to contain hCG in concentrations ranging from 25 to >1000 mt. unita/L, when assayed with a murine monoclonal antibody two-site IRMA for hCG. This system is less sensitive than the interference assay in detecting antibody-binding substances, owing in part to the higher binding required for a positive result in the hCG assay. Because of the greatly increased binding of the hCG standard relative to that of the bindingsubstance, apparent hCG concentrations in interference-assay-positive samples can be substantially reduced by incubating the hCG IRMA mixture overnight. Not only do these binding substances link the capture and signal antibodies, but when bound to antibody they appear to cause a decrease in hCG recognition owing to steric mechanisms (data not shown), leading to low analytical recovery of added hCG.
There have been only isolated reports of interference by these substancesin other murine two-site immunoassays, which contrasts with the 15% false-positive rate obtained in the two-site iRMA for hCG used in this study.Hunter et al. reduces the possibility of these interfering substances binding to the reagent antibodies (Figure 9) . Addition of mouse serum as a source of immunoglobulin is an easy way to decrease the incidence of interference by these antibodybinding substances. The addition of nonimmune serum has previously been advocated by several groups (2, 3, 5, 7) . However, interferenceby antibody-binding substance is still possible if these substances have a high binding capacity. Samples in which the estimated analyte concentrationis not consistentwith the clinical picture should be investigated for this form of interference. Where an interference assay is not available, the addition of more nonspecificimmunoglobulin or immunoglobulinfrom another species could be tried. In the caseof interferencethis shouldresult in lower apparent concentrations ofthe analyte. Sampledilution may not beinformative becausethe antibody-bindingsubstancemay dilute in parallel to the standard, but low analytical recovery of added analyte would indicate this form of interference. Re-assay with use of another immunoassay system for that analyte may also be useful. A systeminvolving rabbit antibodiesis preferable,becausethe binding substances detected with a murine systemusually do not bind to rabbit antibodies (data not shown).
These multivalent antibody-binding substances have been detectedin a murine antibody system, but they also bind to immunoglobulin from other species,and in all sampleswe tested they bound both bovineand horse immunoglobulin. Interference by these substances has also been detectedin two-site immunoassays involving sheep (2), goat (1), and rabbit (3) antibodies. Although they do not bind to the analyte-binding site of the antibody, their presence conceivablycouldalso causeinterference in other immunoassay systems, owing to steric inhibition of analyte binding. Despite only scattered reports of interference by these substances in two-site immunoassays, the potential for interference in immunoasaaysis much greater.
